Friday September 18, 2020

Tysabri could be a €3bn drug says Elan

UPDATE: Pharma company Elan saw its share price shoot up after its chairman said that its multiple sclerosis treatment Tysabri may become a $3 billion drug.

24th May, 2012
Elan: share price rises

Dublin-based pharma company Elan saw its share price shoot up after its chairman said that its multiple sclerosis treatment Tysabri may become a $3 billion drug.

At 1500 the shares were trading up 2.8 per cent while the broader market was up one per cent.

Speaking at the company’s AGM, Robert Ingram also said that he expects probable clarity this year on the company’s Alzheimer’s compound Bapineuzumab. Elan collaborates on that drug with Pfizer in a 50:50 joint...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The best writing and and the biggest stories of 2019 from the Business Post

Richie Oakley | 8 months ago

Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals

Leanna Byrne | 4 years ago